Last updated on November 2018

Observational Study of Pertuzumab Safety in Participants With Breast Cancer


Brief description of study

This Phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) will evaluate the safety of pertuzumab in approximately 3000 participants with metastatic or locally unresectable recurrent breast cancer who have never received chemotherapy or anti-human epidermal growth factor receptor 2 (HER2) therapy for their metastatic disease with HER2 positivity in Korea. Participants who are administered with pertuzumab according to medical opinions of the doctor in charge of surveillance will be registered for this study and treated with pertuzumab under the approval conditions of the product in Korea.

Clinical Study Identifier: NCT02266173

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: ML29299 ...

Chonnam National University Hwasun Hospital
Jeollanam-do, Korea, Republic of
  Connect »